RU2766582C2 - Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) - Google Patents

Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) Download PDF

Info

Publication number
RU2766582C2
RU2766582C2 RU2019121086A RU2019121086A RU2766582C2 RU 2766582 C2 RU2766582 C2 RU 2766582C2 RU 2019121086 A RU2019121086 A RU 2019121086A RU 2019121086 A RU2019121086 A RU 2019121086A RU 2766582 C2 RU2766582 C2 RU 2766582C2
Authority
RU
Russia
Prior art keywords
antibody
seq
antigen
antibodies
human
Prior art date
Application number
RU2019121086A
Other languages
English (en)
Russian (ru)
Other versions
RU2019121086A (ru
RU2019121086A3 (enExample
Inventor
Франк Дж. КАЛЬЦОНЕ
Хай ЯНЬ
Джон ЧЖАН
Original Assignee
Ремд Биотерапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ремд Биотерапьютикс, Инк. filed Critical Ремд Биотерапьютикс, Инк.
Publication of RU2019121086A publication Critical patent/RU2019121086A/ru
Publication of RU2019121086A3 publication Critical patent/RU2019121086A3/ru
Application granted granted Critical
Publication of RU2766582C2 publication Critical patent/RU2766582C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2019121086A 2016-12-23 2017-12-23 Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) RU2766582C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438622P 2016-12-23 2016-12-23
US62/438,622 2016-12-23
PCT/US2017/068369 WO2018119475A1 (en) 2016-12-23 2017-12-23 Immunotherapy using antibodies that bind programmed death ligand-1 (pd-l1)

Publications (3)

Publication Number Publication Date
RU2019121086A RU2019121086A (ru) 2021-01-25
RU2019121086A3 RU2019121086A3 (enExample) 2021-09-03
RU2766582C2 true RU2766582C2 (ru) 2022-03-15

Family

ID=62627185

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019121086A RU2766582C2 (ru) 2016-12-23 2017-12-23 Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)

Country Status (6)

Country Link
US (1) US11332531B2 (enExample)
EP (1) EP3559045A4 (enExample)
JP (1) JP7128529B2 (enExample)
CN (1) CN110337448B (enExample)
RU (1) RU2766582C2 (enExample)
WO (1) WO2018119475A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
CN112424225B (zh) * 2018-03-29 2023-08-11 桂林三金药业股份有限公司 抗pd-l1抗体及其用途
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
JP2023511362A (ja) * 2020-01-21 2023-03-17 ボルト バイオセラピューティクス、インコーポレーテッド 坑ｐｄ－ｌ１抗体
JP7745556B2 (ja) 2020-02-21 2025-09-29 マクロジェニクス，インコーポレーテッド Ｃｄ１３７結合分子及びその使用
US12655229B2 (en) * 2020-03-18 2026-06-16 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies
CN115702003A (zh) * 2020-04-23 2023-02-14 瑞美德生物医药科技有限公司 趋化因子受体4(cxcr4)拮抗剂抗体
EP4352108A4 (en) * 2021-06-09 2026-01-07 Shanghai Epimab Biotherapeutics Co Ltd BISPECIFIC ANTIBODIES AND BINDING PROTEINS THAT BIND TO OX40 AND/OR PD-L1 MOLECULES
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
CA3232777A1 (en) * 2021-08-18 2023-02-23 Remd Biotherapeutics, Inc. Novel interferon variants and bifunctional fusion molecules thereof
US20260193356A1 (en) * 2022-12-19 2026-07-09 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-pdl1 antibodies and uses thereof
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
CN117126282B (zh) * 2023-10-26 2024-01-12 迈威(上海)生物科技股份有限公司 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005874A2 (en) * 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2013079174A1 (en) * 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL153375A0 (en) 2000-06-22 2003-07-06 Genentech Inc Agonist anti-trk-c monoclonal antibodies
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
EP1544291A4 (en) 2002-07-19 2006-08-02 Towa Kagaku Co Ltd A NEW METHOD FOR THE PRODUCTION OF ANTIBODY CYME, NEW ANTIBODY CYM AND USE THEREOF
KR100882445B1 (ko) 2007-03-16 2009-02-09 울산대학교 산학협력단 항―４－１ｂｂ 항체를 이용한 항원 특이적 자가유래ｃｄ８＋ｔ 세포의 분리 및 증식 방법
ES2536772T3 (es) * 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
US20110311550A1 (en) * 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment
MX356367B (es) * 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
CA2748990A1 (en) * 2008-12-26 2010-07-01 The University Of Tokyo Diagnosis and treatment of cancer using anti-lgr7 antibody
WO2010109924A1 (ja) * 2009-03-25 2010-09-30 国立大学法人東北大学 Ｌｈ型二重特異性抗体
JP2012034668A (ja) * 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
US20120189633A1 (en) * 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
CA2833636A1 (en) * 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
CA2971734C (en) * 2014-12-22 2025-11-18 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
CN107250161A (zh) 2015-01-26 2017-10-13 宏观基因有限公司 包含dr5‑结合结构域的多价分子

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005874A2 (en) * 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2013079174A1 (en) * 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAIDONG DONG et al., Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion, NATURE MEDICINE, 2002, Vol.8, no.8, pp.793-800. *
HAIDONG DONG et al., Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion, NATURE MEDICINE, 2002, Vol.8, no.8, pp.793-800. КАДАГИДЗЕ З.Г. и др., Рецепторы лимфоцитов, регулирующие иммунный ответ - ключ к управлению противоопухолевым иммунитетом, ВОПРОСЫ ОНКОЛОГИИ, 2015, том 61, номер 4, с.523-529. *
КАДАГИДЗЕ З.Г. и др., Рецепторы лимфоцитов, регулирующие иммунный ответ - ключ к управлению противоопухолевым иммунитетом, ВОПРОСЫ ОНКОЛОГИИ, 2015, том 61, номер 4, с.523-529. *

Also Published As

Publication number Publication date
JP7128529B2 (ja) 2022-08-31
CN110337448B (zh) 2023-08-08
JP2020514277A (ja) 2020-05-21
EP3559045A4 (en) 2020-08-19
US20200190197A1 (en) 2020-06-18
RU2019121086A (ru) 2021-01-25
EP3559045A1 (en) 2019-10-30
WO2018119475A1 (en) 2018-06-28
RU2019121086A3 (enExample) 2021-09-03
CN110337448A (zh) 2019-10-15
US11332531B2 (en) 2022-05-17

Similar Documents

Publication Publication Date Title
US11332531B2 (en) Immunotherapy using antibodies that bind programmed death ligand-1 (PD-L1)
US11319372B2 (en) Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4)
US12617857B2 (en) Chemokine receptor 4 (CXCR4) antagonist antibodies
EP4281484B1 (en) Anti-her-2/trop-2 constructs and uses thereof
US11242398B2 (en) Anti-OX40 antibodies and methods of activating OX40
US11248049B2 (en) Immunotherapy using antibodies that bind Programmed Death 1 (PD-1)
CN113683695A (zh) 抗cxcr4抗体及抗体-药物缀合物
US20260109770A1 (en) C-c chemokine receptor type 8 (ccr8) antagonist antibodies
CN115803062B (zh) 滋养层细胞表面抗原2(trop-2)抗体
EP4171749A1 (en) Humanized antibodies against lewis y
CN112203685A (zh) 使用结合白细胞介素-17a(il-17a)的抗体的自身免疫紊乱和炎性紊乱的治疗